Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?

To: Rande Is who wrote (19714)	1/31/2000 1:00:00 PM
From: lightfoot	Respond to of 57584

TCLN gets 2 patents! This might be of interest (COMTEX) B: Techniclone Issued Patents On Vascular Targeting Agent Te B: Techniclone Issued Patents On Vascular Targeting Agent Technology TUSTIN, Calif., Jan 31, 2000 (BUSINESS WIRE) -- Techniclone Corporation (NASDAQ:TCLN) today announced that the U.S. Patent Office has granted two patents, US Patent #6,004,554 and US Patent #6,004,555, that extend patent coverage for Techniclone's Vascular Targeting Agent (VTA) technology. The VTA technology is one of Techniclone's platform technologies for the treatment of solid tumors. It is designed to specifically target and occlude tumor blood vessels resulting in an anti-tumor effect. Techniclone's VTA patent portfolio covers agents designed to target a tumor blood vessel and agents designed to kill a tumor through the disruption of the tumor endothelial cells or by causing a blood clot to form in the tumor blood vessels. These newly issued patents specifically cover further cancer treatment methods using compositions that target the blood vessels of solid tumors and enhance the already impressive Techniclone portfolio of 14 issued and a number of allowed US patents in this area. US Patent #6,004,555, in particular, strengthens Techniclone's patent coverage for therapies designed to induce clot formation in tumor vasculature, and covers the use of a wide range of targeted effectors that directly or indirectly induce tumor vessel-specific coagulation. The VTA technology was developed to be used as a front-line therapy or in conjunction with other cancer therapeutic agents for the treatment of solid tumors. Preclinical studies in animal models have shown that treatment with a VTA therapeutic agent can result in significant anti-tumor effects and in some cases complete remission of the treated tumor. Animal studies for the VTA technology were conducted at the University of Texas Southwestern Medical Center at Dallas under the leadership of Dr. Philip Thorpe, the inventor of the VTA technology. Dr. Thorpe stated "We are presently investigating several tumor blood vessel markers that in conjunction with the appropriate killing agent or coagulating factor could become clinical candidates in the near future. These newly issued patents ensure our ability to move these candidates forward." Dr. John Bonfiglio, Techniclone's Interim President, stated, "The issuance of these patents further solidifies Techniclone's intellectual property position in the area of vascular targeting. We will continue to build a strong patent portfolio to protect our technology and to help in attracting licensing partners capable of commercializing this promising platform technology. Many pharmaceutical companies currently developing anti-angiogenesis therapies will view this area as complementary to their existing programs. Ideally, the same tumor targets that these companies are currently examining with anti-angiogenesis agents could also be ideal targets for our Vascular Targeting Agents." Company Overview: Techniclone Corporation is a biopharmaceutical company focused on the development, commercialization and licensing of unique technologies for the treatment of cancer, primarily based on its "collateral targeting technologies". These technologies therapeutically target cell structures and cell types, rather than surface cancer cells, as a means to attack solid tumors, without causing damage to surrounding healthy tissue. The Company has three collateral targeting technologies: Cotara(TM), Vasopermeation Enhancement Agents (VEA), and Vascular Targeting Agents (VTA). The Company also has a direct tumor targeting agent Oncolym(R) for the treatment of advanced non-Hodgkin's B-cell Lymphoma which has been licensed to Schering AG, Germany, which is now responsible for all existing and future Oncolym(R) clinical trial programs as well as marketing. Additional information on the Company and its products can be found at www.techniclone.com. Safe Harbor Statement: This release may contain certain forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ from the Company's expectations as a result of risk factors discussed in Techniclone's reports on the file with the U.S. Securities and Exchange Commission, including, but not limited to, the Company's report on Form 10K for the year ended April 30, 1999 and Form 10Q for the quarter ended October 31, 1999. Copyright (C) 2000 Business Wire. All rights reserved. Distributed via COMTEX. -0- CONTACT: DeMonte Associates Cynthia DeMonte 212-420-0088 WEB PAGE: businesswire.com GEOGRAPHY: NEW YORK CALIFORNIA INDUSTRY CODE: BIOTECHNOLOGY PHARMACEUTICAL MEDICAL Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. * end of story *

To: Rande Is who wrote (19714)	1/31/2000 1:31:00 PM
From: carepedeum2000	Read Replies (1) \| Respond to of 57584

rande- if you like cra, you will love affx, very strong stock, this one will roar when sector comes back, "biochip"